Cargando…

Intralesional cidofovir for the management of refractory cutaneous verrucae: a review of applications and opportunities

Viral warts – manifestations of cutaneous infection by human papilloma virus – can be a significant physical and emotional burden for patients when common treatments fail, particularly for individuals who are immunocompromised or with multiple lesions. Cidofovir, an antiviral agent typically used fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, William C., Lau, Charles B., Frangos, Jason E., Nambudiri, Vinod E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088403/
https://www.ncbi.nlm.nih.gov/pubmed/37056449
http://dx.doi.org/10.1177/20499361231165862
Descripción
Sumario:Viral warts – manifestations of cutaneous infection by human papilloma virus – can be a significant physical and emotional burden for patients when common treatments fail, particularly for individuals who are immunocompromised or with multiple lesions. Cidofovir, an antiviral agent typically used for the treatment of cytomegalovirus infection, has emerged as an alternative treatment option for viral warts when administered topically or intralesionally. In this review, we highlight the scientific rationale, published evidence, and practical clinical uses of intralesional cidofovir for the management of cutaneous warts as well as ongoing questions requiring further research and exploration of this emerging therapy for refractory verrucae.